ANRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alto Neuroscience Inc (ANRO) is not a strong buy at this time for a beginner investor with a long-term strategy. Despite some positive technical indicators and analyst optimism, the stock's recent price decline, weak financial performance, lack of significant trading signals, and competitive pressure in the market suggest holding off on investment until clearer positive trends emerge.
The stock shows mixed signals. MACD is positive and contracting, indicating mild bullish momentum. RSI is neutral at 61.135, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock has recently declined by 3.97% in the regular market, and candlestick pattern analysis predicts further short-term declines (-0.81% in the next day, -3.83% in the next week, -3.01% in the next month). Key support is at 17.7, and resistance is at 21.131.
Analyst Thomas Shrader raised the price target to $28, citing the company's innovative approach to precision psychiatry and promising ALTO-101 trial. The DEA's increased psilocybin production quota highlights potential growth in the mental health treatment market.
Hedge funds are selling heavily, with a 159.20% increase in selling activity last quarter. Competitor Helus Pharma has reported significant clinical trial successes, which could overshadow Alto Neuroscience's market position. Additionally, the stock has been underperforming in the short term, with a -3.97% regular market decline and bearish short-term forecasts.
The company's Q3 2025 financials show no revenue growth (0% YoY), a net income drop of -15.50% YoY to -$14.18M, and an EPS decline of -16.13% YoY to -$0.52. These metrics indicate weak financial health and no clear growth trajectory.
Analyst Thomas Shrader from BTIG maintains a Buy rating and raised the price target from $27 to $28, citing the company's innovative approach to precision psychiatry and the ALTO-101 trial's potential. However, this optimism is not supported by strong financial or market performance at this time.
